Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease

Lam Anh Nguyet, Tran Tan Thanh, Le Nguyen Thanh Nhan, Nguyen Thi Thu Hong, Le Nguyen Truc Nhu, Hoang Minh Tu Van, Nguyen Thi Han Ny, Nguyen To Anh, Do Duong Kim Han, Ha Manh Tuan, Vu Quang Huy, Ho Lu Viet, Hoang Quoc Cuong, Nguyen Thi Thanh Thao, Do Chau Viet, Truong Huu Khanh, Louise Thwaites, Hannah Clapham, Nguyen Thanh Hung, Nguyen Van Vinh Chau, Guy Thwaites, Do Quang Ha, H. Rogier van Doorn, Le Van Tan

Hand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after the onset of illness from HFMD patients infected with enterovirus A71 (EV-A71), coxsackievirus A (CVA) 6, CVA10, and CVA16 to study cross-neutralization. For homotypic viruses, seropositivity increased from <60% at enrollment to 97%–100% at follow-up, corresponding to seroconversion rates of 57%–93%. Seroconversion for heterotypic viruses was recorded in only 3%–23% of patients. All plasma samples from patients infected with EV-A71 subgenogroup B5 could neutralize the emerging EV-A71 subgenogroup C4. Collectively, our results support previous reports about the potential benefit of EV-A71 vaccine but highlight the necessity of multivalent vaccines to control HFMD.

Since 1997, hand, foot and mouth disease (HFMD) has emerged as a serious childhood infection in the Asia–Pacific region (1,2) with the potential of spreading to other parts of the world. Indeed, HFMD epidemics, especially those caused by enterovirus A71 (EV-A71), have increasingly been reported worldwide, including in the United States and Europe (3–5). Although HFMD is a mild infection in most cases, severe clinical complications (e.g., central nervous system involvement as brainstem encephalitis) may happen and can be fatal (1,6). However, no antiviral drugs are available to the affected patients, including those with severe clinical phenotypes.

HFMD is caused by various serotypes of enterovirus A of the family Picornaviridae. Of these, EV-A71, coxsackievirus A (CVA) 6, CVA10, and CVA16 are the most common pathogens isolated from patients with clinically suspected HFMD, with CVA6 being increasingly reported (7–9). In Vietnam, our recent report showed that of 1,547 patients with HFMD enrolled in a clinical study, EV-A71 was detected in 24.4%, followed by CVA6 (21.8%), CVA16 (10.8%), and CVA10 (7.9%). Other enteroviruses detected sporadically included CVA4 (1.7%), CVA12 (1.4%), and CVA2 (0.6%) (10). Infection with EV-A71 has received more attention because it frequently causes severe HFMD, especially in recent outbreaks recorded in the Asia–Pacific region since 1997 (6,11). Consequently, inactivated monovalent vaccines for EV-A71 have been successfully developed and licensed in China (12–14). The use of those vaccines, however, has been voluntary and restricted within mainland China.

Because the viruses causing HFMD are diverse, ongoing efforts exist to develop multivalent vaccines, especially those including antigens of the aforementioned common serotypes (15). Results from these preclinical studies using animal models showed a lack of cross-reactivity among EV-A71, CVA6, CVA10, and CVA16 (16,17). There is, however, scarce information about to what extent human infection with 1 HFMD-causing enterovirus serotype can elicit (cross-)neutralizing antibodies...
against homotypic and heterotypic enterovirus serotypes. Such data are of paramount importance to support the development of intervention strategies (including vaccines) and the design of epidemiologic research on surveillance and transmission dynamics of HFMD and will contribute to the expanded knowledge about host–pathogen and pathogen–pathogen interaction of this emerging clinical problem. We aim to fill the existing gaps in knowledge about seropositivity and (cross-)neutralization elicited as a consequence of human infection by EV-A71, CVA6, CVA10, and CVA16, the 4 most common serotypes responsible for the ongoing epidemic of HFMD worldwide, especially in Asia.

Materials and Methods

Settings
The clinical and patient data used in this study were derived from an ongoing clinical study of HFMD that has been conducted at Children’s Hospital (CH) 1, CH2, and the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam, since 2013 (6,8). These hospitals are tertiary referral centers for children with HFMD in Ho Chi Minh City and southern Vietnam, covering a catchment population of >40 million.

Patient Enrollment and Data Collection
We screened all patients <12 years of age who came to outpatient departments or were admitted to inpatient wards of CH1, CH2, or HTD with a clinical diagnosis of HFMD and, if outpatients, an illness of <3 days for enrollment in our study. We excluded any patient for whom the attending physician believed another diagnosis was more likely.

We collected information regarding demographics, clinical signs/symptoms, clinical grades, treatments, laboratory tests, length of hospital stay, and outcomes. In addition, for enterovirus serotype determination, we sampled acute throat and rectal swabs at enrollment and collected a plasma sample from each participant at enrollment and 7–14 days after enrollment.

HFMD Clinical Grade Classification
According to the Vietnamese Ministry of Health, HFMD is clinically divided into 4 major grades. Grade 1 is assigned to patients with mouth ulcers or vesicles/papules on hands, feet, or buttocks, with or without mild fever (<39°C). Grade 2 is further divided into grade 2A (central nervous system [CNS] involvement, myoclonus reported by parents or caregivers only, fever >39°C or ataxia), grade 2B1 (myoclonus observed by medical staff or history of myoclonus and lethargy or pulse >130 bpm), and grade 2B2 (ataxia, cranial nerve palsies, limb weakness, nystagmus, persistent high fever, or pulse >150 bpm). Grade 3 involves autonomic dysfunction with sweating, hypertension, tachycardia, and tachypnea. Grade 4 is for disease with additional cardiopulmonary compromise with pulmonary edema or shock syndrome (18). Patients with grade 2B1 or above are considered to have severe HFMD, and often require intravenous immunoglobulin administration.

Determination of Enterovirus Serotype and EV-A71 Subgenogroup
We determined enterovirus serotype using a combination of PCR and sequencing approaches (19–21). In brief, we first extracted viral RNA from throat/rectal swab specimens. We then used a 1-step multiplex real-time reverse transcription PCR assay to simultaneously detect all enterovirus serotypes and EV-A71 (19). We then tested all specimens positive for enterovirus serotype or EV-A71 to further identify specific enterovirus serotypes or EV-A71 subgenogroups, using a combination of viral protein (VP) 1 PCR and sequencing of the obtained PCR amplicon (18,20,21). Finally, we analyzed the obtained VP1 sequences using a previously described online tool to determine enterovirus serotype or EV-A71 subgenogroup (22).

Selection of Patients and Plasma Sample for Microneutralization Assay
From this study, we selected a convenience sample of 120 patients (30 per serotype CVA6, CVA10, CVA16, and EV-A71) who had plasma samples collected at enrollment and follow-up and were available for immunological response analysis. In addition, for assessment of antigenic difference between subgenogroup B5 (circulating in Vietnam during 2013–2015) and C4 (circulating in Vietnam in 2018), we included 1 available follow-up plasma sample collected from a fatal case, in which the patient was infected with subgenogroup C4 during the 2018 outbreak (6).

Viral Strains
We isolated representative samples of CVA10, CVA16, and EV-A71 (including EV-A71 subgenogroup B5 in 2013 and C4 in 2018) used for microneutralization assay from patients with HFMD who were enrolled in the clinical study (7,8,10). We obtained a CVA6 isolate from the virus archive of Pasteur Institute in Ho Chi Minh City. For EV-A71, unless specified, all neutralization experiments were carried out using EV-A71 subgenogroup B5.
We performed the microneutralization as previously described (23). In brief, we first inactivated plasma samples at 56°C for 30 min, and then diluted the samples in serial ratios from 1:8 to 1:512 in maintenance medium (Sigma-Aldrich, https://www.sigma-aldrich.com). Accordingly, the lower limit of detection of the assay was 1:8 and the upper limit was 1:512. Next, we incubated plasma dilutions with an equal volume of 100 times the median culture of infectious dose (TCID\textsubscript{50}) of the virus at 37°C for 1 hour, and then transferred them into a 96-well plate precoated with human rhabdomyosarcoma (RD) cells (American Type Culture Collection, https://www.atcc.org). The plate was then incubated in a 5% carbon dioxide incubator at 37°C. Cells were observed daily for cytopathic effects. The antibody titer of the sample was determined by the highest plasma dilution that prevented cytopathic effects in 50% of the wells. We tested each dilution in quadruplicate and included negative and positive controls in each experiment. We defined seropositivity as neutralizing antibody titer >1:8. We defined seroconversion as a change from seronegativity to seropositivity, or at least a 4-fold rise in the neutralizing antibody titer between enrollment and follow-up time points.

Statistical Analysis
We performed statistical analyses of clinical data using IBM SPSS Statistics 23 (IBM Corp., https://www.ibm.com). We compared categorical variables using a χ\textsuperscript{2} test or Fisher exact test and compared continuous variables using the Mann-Whitney U-test, 1-way analysis of variance (ANOVA) test, or Kruskal-Wallis test. We tested the difference in neutralizing antibody titers between samples obtained at enrollment and follow-up using the Wilcoxon matched-pairs signed rank test, available in Prism 5.04 (GraphPad Software, https://www.graphpad.com).

The institutional review boards of CH1, CH2, and HTD, as well as the Oxford Tropical Research Ethics Committee (OxTREC), approved the study. We obtained written informed consent from a parent or guardian of each enrolled patient.

Results

Baseline Characteristics of Patients
We compiled the baseline characteristics and clinical outcome of 120 patients included for analysis of neutralizing antibody responses to all 4 enterovirus serotypes (EV-A71, CVA6, CVA10, and CVA16) (Table 1). All patients were enrolled in the clinical study during July 2013–March 2017. Male patients were predominant (female/male ratio 45/75). Thirteen (10.8%) patients had severe HFMD (grade 2B1 or above); 119 patients (99.2%) made a complete recovery. Following the onset of illness, 50% of the patients were admitted to hospital within 1 day (range 0–5 days) and were enrolled in the clinical study within 2 days (range 0–6 days). All second/follow-up plasma samples included for analysis were collected at day >7 (median 9 days, range 7–17) after the illness onset.

Of the 30 patients infected with EV-A71, detailed information about subgenogroup was successfully generated for 13 patients, who were all positive for subgenogroup B5. Of the patients with EV-A71 infections, 20% had severe clinical phenotypes (grade 2B1 or above), whereas severe outcome was recorded in 3.3% of patients infected with CVA6, 6.7% of patients infected with CVA10, and 13.3% of patients infected with CVA16 (Table 1). Mouth lesion distributions and C-reactive protein levels were statistically different among serotypes. Otherwise, there were considerable similarities between groups of patients who were infected with EV-A71, CVA6, CVA10, or CVA16 in terms of clinical characteristics and outcome, as well as blood biochemistry parameters (Table 1), in agreement with a previous report (8).

Seropositivity and Seroconversion
We compiled the results of seropositivity testing at enrollment (baseline) and follow-up (Table 2). Although 60% (18/30) of patients infected with EV-A71 had specific antibodies to EV-A71 at the measured level (>1:16) or above in their blood samples, most of the patients (>70%) infected with CVA6, CVA10, or CVA16 had no specific antibodies to the infecting viruses at enrollment. The proportion of patients with antibodies against heterotypic viruses ranged from 7% (2/30) of CVA6 patients having neutralizing antibodies against EV-A71 to 57% (17/30) of EV-A71 patients having antibodies against CVA10.

At follow-up (>7 days after the onset of illness), seropositivity for homotypic viruses reached 97%–100% in all patient groups; comparisons for seropositivity rates at enrollment and follow-up were all significant (p<0.001) (Table 2), corresponding to seroconversion rates of 57% (17/30) for EV-A71, 77% (23/30) for CVA16, 83% (25/30) for CVA10, and 93% (28/30) for CVA6 (Table 2). We found no difference in antibody responses (seropositivity and seroconversion) between the groups of patients who were positive for EV-A71 subgenogroup B5 and those from whom EV-A71 subgenogroup was not available (data not shown).
Neutralizing Antibodies in Patients with HFMD

| Table 1. Baseline characteristics and clinical outcome of the patients included in study of patients with hand, foot and mouth disease, Vietnam* |
|-----------------------------------------------|
| Characteristics | All, N = 120 | EV-A71, N = 30 | CVA6, N = 30 | CVA10, N = 30 | CVA16, N = 30 | p value† |
| Demographics | | | | | | |
| Sex ratio, F/M | 45/75 | 8/22 | 8/22 | 14/16 | 15/15 | 0.12 |
| Median age, mo (range) | 16.2 (1.8–59) | 16.7 (4.9–58.6) | 16.4 (5.3–59) | 14.7 (1.8–41.4) | 19 (5.8–46.5) | 0.11 |
| Median day of illness from onset (range) | | | | | | |
| To hospital admission | 1 (0–5) | 2 (0–4) | 1 (0–3) | 1 (0–3) | 1 (0–5) | 0.058 |
| To enrollment in study | 2 (0–6) | 2 (0–4) | 1.5 (0–3) | 2 (0–6) | 2 (0–6) | 0.802 |
| To collection of second plasma | 9 (7–17) | 9 (7–12) | 9 (7–14) | 9 (7–14) | 9 (8–17) | 0.211 |
| Median day of hospitalization‡ | 3 (1–12) | 4 (2–10) | 3 (1–8) | 3 (1–6) | 4 (2–12) | 0.3 |
| Inpatient/outpatient ratio | 77/43 | 17/13 | 18/12 | 25/5 | 17/13 | 0.08 |
| Clinical characteristics, no. (%) | | | | | | |
| Fever | 87 (72.5) | 24 (80) | 17 (56.7) | 24 (80) | 17 (56.7) | 0.16 |
| Cough | 26 (21.7) | 6 (20) | 2 (6.7) | 8 (26.7) | 10 (33.3) | 0.06 |
| Runny nose | 21 (17.5) | 6 (20) | 3 (10) | 5 (16.7) | 7 (23.3) | 0.63 |
| Vomiting | 25 (20.8) | 7 (23.3) | 5 (16.7) | 5 (16.7) | 8 (28.7) | 0.77 |
| Diarrhea | 14 (11.7) | 3 (10) | 3 (10) | 5 (16.7) | 5 (16.7) | 0.89 |
| Drowsiness | 6 (5) | 2 (6.7) | 0 | 2 (6.7) | 2 (6.7) | 0.6 |
| Irritability | 14 (11.7) | 5 (16.7) | 2 (6.7) | 5 (16.7) | 2 (6.7) | 0.46 |
| Myoclonus | 30 (25) | 10 (33.3) | 3 (10) | 9 (30) | 8 (27) | 0.13 |
| Sweating | 4 (3.3) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 1 |
| Lethargy | 2 (1.7) | 0 | 0 | 2 (6.7) | 0 | 0.24 |
| Conjunctivitis | 1 (0.8) | 0 | 1 (3.3) | 0 | 0 | 1 |
| Rash | 106 (88.3) | 30 (100) | 30 (100) | 17 (56.7) | 19 (63.3) | 0 |
| Mouth lesion | 111 (92.5) | 28 (93.3) | 23 (76.7) | 30 (100) | 30 (100) | 0.001 |
| Limb weakness | 4 (3.3) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 0.8 |
| Median pulse, bpm (range) | 120 (96–180) | 120 (96–180) | 120 (100–167) | 125 (100–165) | 120 (100–170) | 0.632 |
| Median blood pressure, mm Hg (range) | | | | | | |
| Systolic | 90 (75–128) | 90 (75–100) | 90 (80–120) | 90 (80–120) | 90 (80–128) | 0.661 |
| Diastolic | 60 (40–80) | 55 (50–62) | 55 (40–80) | 60 (50–80) | 60 (50–77) | 0.551 |
| Blood biochemistry results, median (range) | | | | | | |
| Leukocyte count, × 10⁹ cells/L | 13.1 (1–50.6) | 13.6 (7.8–50.6) | 12.5 (1–25.9) | 14.3 (5–24.7) | 12.4 (4.5–24.4) | 0.638 |
| Neutrophils, % | 51 | 51.2 | 52.7 | 47.6 | 50.9 | 0.658 |
| (2.1–92.7) | (19.7–72.8) | (7.7–92.7) | (2.1–76.3) | (24.2–86.1) | |
| Lymphocytes, % | 37.1 | 37.1 | 33.9 | 37.6 | 36.5 | 0.846 |
| (3.7–80.2) | (18.4–65.5) | (3.7–80.2) | (17.6–71.2) | (6.1–60.3) |
| Platelet count, × 10⁹/L | 325.5 | 360 | 341.5 | 287 | 293.5 | 0.086 |
| (96–597) | (189–522) | (150–513) | (96–452) | (175–597) |
| Glucose, mg/dL | 107 (0–212) | 112 (62–170) | 108.5 (0–154) | 108.5 (68–212) | 98.5 (51–164) | 0.324 |
| C-reactive protein, mg/dL | 12.4 (0–102) | 4.1 (0–100) | 13.7 (0–102) | 23.3 (3–58) | 9.9 (0–39) | <0.001 |
| Clinical grade, no. (%) | | | | | | |
| Mild | 107 (89.2) | 24 (80) | 29 (96.7) | 28 (93.3) | 26 (86.7) | 0.2 |
| Severe | 13 (10.8) | 6 (20) | 1 (3.3) | 2 (6.7) | 4 (13.3) | |
| IVIg administration, no. (%) | 8 (6.7%) | 3 (10) | 1 (3.3) | 1 (3.3) | 3 (10) | 0.5 |
| Outcome, no. (%) | | | | | | |
| Full recovery | 119 (99.2) | 30 (100) | 29 (96.7) | 30 (100) | 30 (100) | 0.17 |
| Incomplete recovery | 1 (0.8) | 0 | 1 (3.3) | 0 | 0 |

*CV, coxsackievirus; EV, enterovirus; IVIg, intravenous immunoglobulin.†Results of statistical analyses comparing individual groups of patients infected with EV-A71, CVA6, CVA10, or CVA16.‡Inpatients only.

The difference in the proportion of patients who were seropositive for heterotypic viruses was not statistically significant between the enrollment and follow-up time points (Table 2). At follow-up, seroconversion for heterotypic viruses was recorded in only 3% (1/30) to 23% (7/30) of the patients, with comparable rates across serotypes (Table 2). For example, of the 30 patients infected with CVA16, seroconversions for CVA6 were recorded in 10%, seroconversions for CVA10 in 7%, and seroconversions for EV-A71 in 7%. Similarly, of the 30 patients infected with EV-A71, seroconversions for CVA6 were recorded in 13%, seroconversions for CVA10 in 3%, and seroconversions for CVA16 in 10%. Five patients became seronegative for heterotypic viruses at follow-up (Figures 1, 2; Appendix Figures 1, 2, https://wwwnc.cdc.gov/EID/article/26/2/19-0721-App1.pdf).

Seropositivity versus Illness Day at Enrollment and Patient Age

We found a significant difference in illness days at enrollment between the groups of patients who were seropositive by neutralization testing for any homotypic virus and those who were negative, median day of illness 2 (range 1–6 days) versus 1 (0–6 days) (p<0.001) (Figure 3). Despite the small sample size,
subset analysis demonstrated a similar association between illness day and seropositivity at enrollment among patients infected with EV-A71 and those infected with CVA6 (Appendix Figure 3). We found no difference in age (months) between the groups of patients with and without neutralizing antibodies at enrollment (data not shown).

Kinetics of Neutralizing Antibody Titers
To further shed light on the kinetics of neutralizing antibody titers over the course of illness, we plotted and compared the neutralizing antibody titers against homotypic and heterotypic enterovirus serotypes at enrollment and follow-up time points (Table 3; Figures 1, 2; Appendix Figures 1, 2). Overall, the antibody

![Figure 1. Kinetics of neutralizing antibody titers in plasma samples collected at enrollment and follow-up from patients infected with EV-A71 in study of patients with hand, foot and mouth disease, Vietnam. A) CVA6 (p = 0.073); B) CVA10 (p = 0.347); C) CVA16 (p = 0.250); D) EV-A71 (p<0.001). CV, coxsackievirus; EV, enterovirus.](image-url)
Neutralizing Antibodies in Patients with HFMD

Neutralizing antibody titers to homotypic enteroviruses at follow-up were significantly higher than those measured at enrollment (p < 0.001; Table 3). All patients at follow-up had antibody titers against homotypic viruses ranging from 32 to 512, well above the protective level as defined from vaccine trials (12–14) (Appendix Figures 1, 2).

Neutralizing antibody titers against heterogeneous serotypes measured at the 2 time points were not statistically different, with most patients (15/50–27/30 [50%–90%]) having antibody titers below the assay cutoff (i.e., below the protective level). There was, however, a significant difference in antibody titer against CVA16 between the 2 time points among patients infected with CVA6 (p = 0.021; Table 3). Subanalysis did not show that samples positive for CVA6 were more likely to be positive for CVA16 or any other serotypes than samples that were negative for CVA6 (Appendix Table 1).

**Antigenic Difference between Subgenogroup B5 and Emerging Subgenogroup C4**

To assess the extent to which infection with subgenogroup B5 circulating during 2013–2015 could elicit cross-neutralizing antibody responses against subgenogroup C4, which emerged in 2018 and caused a large outbreak of >130,000 hospitalizations and 17 deaths in Vietnam (6), we performed a complementary analysis using 6 follow-up plasma samples from the aforementioned group of patients infected with subgenogroup B5. Subsequently, all the included plasma samples could neutralize 2018 subgenogroup C4, and there was no difference in neutralizing antibody titers against the EV-A71 subgenogroups C4 and B5 (Figure 4). Likewise, the only available follow-up plasma sample collected from a patient infected with 2018 subgenogroup C4 had a neutralizing antibody titer of 1:512 against both subgenogroups.

**Discussion**

Despite the public health threat of HFMD, scarce information exists for pathogen–pathogen and host–pathogen interactions, from the immunity perspective, to inform the development and implementation of intervention strategies, especially vaccines, and the design of epidemiologic research on disease surveillance and transmission dynamics. Here we report on the seropositivity, seroconversion, and neutralization in HFMD patients infected with EV-A71, CVA6,
CVA10, or CVA16, the 4 most common enterovirus serotypes responsible for the ongoing HFMD epidemic in Vietnam and the Asia–Pacific region over the past few decades.

In terms of seropositivity, our results showed that antibody response against homotypic viruses at or above the titer of the protective level developed quickly after the onset of illness, with seropositivity for homotypic viruses changing from <60% at day 0–6 after illness onset (at enrollment) to 97%–100% at follow-up (7–19 days after the onset of illness). We could find no existing data obtained from natural infection to compare with our results. However, results obtained from phase 3 vaccine trials have shown that at day 56 after the administration of the first 2 doses of inactivated EV-A71 vaccine, 98.5–99.9% of the volunteers had neutralizing antibody against EV-A71 at titers of >1:16 (12–14). Collectively, these data expand our knowledge about immunogenicity elicited as a consequence of EV-A71 vaccination and natural infection. Coxsackievirus vaccine development has not resulted in >57% of the patients during the course of illness. Furthermore, at follow-up, only a small proportion (3%–23%) of the patients had seroconverted for heterotypic viruses, suggesting that cross-neutralization among EV-A71, CVA6, CVA10, and CVA16 is absent or occurs in only a small proportion of patients (24,25). It cannot, however, be ruled out that these seropositive and seroconversion rates, especially among CVA6 patients, were attributable to previous exposure or co-infection with other serotypes (e.g., CVA16 in the case of CVA6 patients), which may have been undetected by PCR. Our data support a recent report about recurrent HFMD episodes resulting from reinfection with heterotypic serotypes in China (9) and the absence of cross-neutralization among these 4 enterovirus serotypes observed in vaccine studies (13,16,17). As such, multivalent vaccines are needed to control HFMD.

EV-A71 exists as a single serotype but is genetically divided into several genogroups (e.g., A, B, and C) and subgenogroups (e.g., C1–C5 and B1–B5). In Vietnam, HFMD has been a major public health concern since 2011, causing an average of 80,000 hospitalizations per year. The switches between predominant EV-A71 subgenogroups have been well documented; C4 was responsible for the 2011–2012 epidemic in Vietnam and the Asia–Pacific region over the past few decades.

In Vietnam, HFMD has been a major public health concern since 2011, causing an average of 80,000 hospitalizations per year. The switches between predominant EV-A71 subgenogroups have been well documented; C4 was responsible for the 2011–2012 epidemic in Vietnam and the Asia–Pacific region over the past few decades.

Table 3. Geometric mean titers of neutralizing antibodies against enteroviruses in study of patients with hand, foot and mouth disease, Vietnam

| Virus     | Samples    | Geometric mean titer (95% CI) of neutralizing antibodies |
|-----------|------------|--------------------------------------------------------|
|           |            | CVA6 | CVA10 | CVA16 | EV-A71 |
| CVA6      | Enrollment | 4.9 (3.6–6.7) | 13.3 (6.8–26.1) | 6.9 (4.3–11.3) | 5.0 (3.6–7.0) |
|           | Follow-up  | 151.4 (113.0–202.8) | 13.0 (6.4–26.2) | 10.8 (5.6–20.8) | 6.0 (3.8–9.7) |
|           | p value    | <0.001 | 0.83  | 0.021 | 0.50   |
| CVA10     | Enrollment | 6.2 (3.9–9.7) | 10.1 (5.7–17.7) | 5.3 (3.8–7.2) | 5.9 (3.8–9.7) |
|           | Follow-up  | 8.7 (4.8–16.1) | 245.5 (181.1–332.7) | 6.3 (4.0–10.1) | 7.6 (4.3–13.8) |
|           | p value    | 0.063 | <0.001 | 0.098 | 0.50   |
| CVA16     | Enrollment | 9.0 (5.0–16.0) | 13.6 (6.9–26.7) | 10.5 (5.7–18.6) | 7.4 (4.3–12.9) |
|           | Follow-up  | 10.3 (5.7–18.7) | 14.6 (7.5–28.5) | 141.2 (104.547–191.0) | 9.8 (5.1–18.7) |
|           | p value    | 0.25  | 1.0   | <0.001 | 0.098   |
| EV-A71    | Enrollment | 6.6 (4.2–10.4) | 23.2 (11.5–46.7) | 7.6 (4.4–13.0) | 37.7 (17.9–79.4) |
|           | Follow-up  | 9.4 (5.3–16.7) | 18.8 (10.0–35.4) | 10.1 (5.4–18.7) | 295.1 (200.6–334.2) |
|           | p value    | 0.073 | 0.31  | 0.25  | <0.001 |

*p values reflect the results of statistical analysis comparing the geometric mean titers between the 2 time points (enrollment and follow-up) of the corresponding enterovirus serotypes. CV, coxsackievirus; EV, enterovirus; HFMD, hand, foot and mouth disease.

Figure 3. Association between antibody response (seropositive) and illness days at enrollment (p<0.001) in study of patients with hand, foot and mouth disease, Vietnam. There were 82 patients with antibody titers below assay cutoff, and 38 patients with antibody titers above assay cutoff.
Neutralizing Antibodies in Patients with HFMD

outbreak (18) followed by the predominance of B5 during 2013–2015 (10) and the reemergence of C4 in 2018 (6). Of note, the emergence of C4 in 2018 resulted in a severe outbreak that caused >130,000 hospitalizations and 17 deaths. The underlying mechanism that determines the emergence of certain subgenogroups in specific localities remains a puzzle; it may be a consequence of a complex interplay among the pathogen, the hosts, and public health response, of which antigenic evolution might play a role (26,27). The fact that all serum samples from subgenogroup B5—infected patients collected before 2018 could neutralize the 2018 C4 virus suggests that immunity developed as a consequence of natural infection with subgenogroup B5 could provide protection against subgenogroup C4. However, the extent to which waning immunity (28), as observed from vaccine trials, may influence the long-term protection and overall population immunity, in turn resulting in possible reinfection, which has previously been reported in China (9), as well as disease emergence, remains unknown. The underlying mechanism determining the emergence of subgenogroup C4 in Vietnam in 2018 warrants further research.

Our study has some limitations. We based our analysis on only the 4 predominant serotypes currently responsible for the ongoing HFMD epidemics in the Asia–Pacific region, whereas >20 enterovirus serotypes have been reported to be associated with HFMD in the region. Furthermore, because of the unavailability of plasma samples, we were not able to informatively assess the antigenic relationship between EV-A71 subgenogroups responsible for major HFMD outbreaks in Vietnam since 2011 (C4 and B5) with proper sample size. Likewise, our syndromic hospital-based surveillance may have missed atypical HFMD cases. Together with the convenience sample used, these limitations may lower the level of generalizability of the obtained results to some extent. In addition, we were unable to obtain long-term follow-up blood samples from HFMD cases after hospital discharge. Therefore, evaluation of antibody kinetics and the waning antibody profiles of the natural infection beyond the sampling period of the current study remain unknown.

In summary, because human infection with 1 HFMD-causing enterovirus serotype can elicit neutralizing antibodies against homotypic viruses, our results support previous reports about the potential benefit of monovalent EV-A71 vaccine in reducing the incidence of EV-A71–associated HFMD (29). The data also emphasize the requirement for multivalent vaccines to control HFMD. Our results offer evidence that is essential for the development of intervention strategies, especially multivalent vaccines, and the design of seroepidemiologic studies.

Acknowledgments
We thank Le Kim Thanh for her logistics support. We are indebted to the patients who participated in this study. This study was funded by the Wellcome Trust of Great Britain (grant nos.106680/B/14/Z and 204904/Z/16/Z).

About the Author
Ms. Nguyet is a research assistant at Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. She is particularly interested in the application of classical virology methods as virus isolation and neutralization to study viruses responsible for emerging infections (hand, foot and mouth disease) in Vietnam and the region.

References
1. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–105. https://doi.org/10.1016/S1474-4422(10)70209-X
2. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–90. https://doi.org/10.1016/S1473-3099(10)70194-8
3. Österback R, Vuorinen T, Linna M, Susi P, Hyypia T, Waris M. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg Infect Dis. 2009;15:1485–8. https://doi.org/10.3201/eid1509.090438

4. Abedi GR, Watson JT, Nix WA, Oberste MS, Gerber SL. Enterovirus and parechovirus surveillance—United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67:515–8. https://doi.org/10.15585/mmwr.mm6718a2

5. Kimmis BD, Donning C, Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018;102:353–6.

6. Nhan LNT, Hong NTT, Nhu LNT, Nguyen LA, Ny NTH, Thanh TT, et al. Severe enterovirus A71 associated hand, foot and mouth disease, Vietnam. 2018: preliminary report of an impending outbreak. Euro Surveill. 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800590

7. Anh NT, Nhu LNT, Van HMT, Hong NTT, Hang VTT, et al. Emerging coxsackievirus A6 causing hand, foot and mouth disease, Vietnam. Emerg Infect Dis. 2018;24:654–62. https://doi.org/10.3201/eid2404.171298

8. Hoang MTV, Nguyen TA, Tran TT, Vu TTH, Le NTN, Nguyen THN, et al. Clinical and aetiological study of hand, foot and mouth disease in southern Vietnam, 2013–2015: inpatients and outpatients. Int J Infect Dis. 2019;80:1–9. https://doi.org/10.1016/j.ijid.2018.12.004

9. Huang J, Liao Q, Ooi MH, Cowling BJ, Chang Z, Wu P, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008–2015. Emerg Infect Dis. 2018;24. https://doi.org/10.3201/eid2403.171303

10. Van HMT, Anh NT, Hong NTT, Nhu LNT, Nguyen LA, Thanh TT, et al. Enterovirus A71 phenotypes causing hand, foot and mouth disease, Vietnam. Emerg Infect Dis. 2019;25:788–91. https://doi.org/10.3201/eid2504.181367

11. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14:308–18. https://doi.org/10.1016/S1473-3099(13)70342-6

12. Zhu F-C, Meng F-Y, Li J-F, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunogenicity of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–32. https://doi.org/10.1016/S0140-6736(13)62503-7

13. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–37. https://doi.org/10.1056/NEJMoai1303224

14. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–28. https://doi.org/10.1056/NEJMoai1402933

15. Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines. 2018;17:819–31. https://doi.org/10.1080/14760588.2018.1510326

16. Zhang W, Dai W, Zhang C, Zhou Y, Xiong F, Wang S, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:1–12. https://doi.org/10.1002/emm2.12004

17. Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, et al. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36:3445–52. https://doi.org/10.1016/j.vaccine.2018.05.005

18. Khanh TH, Sabanathan S, Thanh TT, Thoa PK, Truong TC, Hang V, et al. Enterovirus 71-associated hand, foot, and mouth disease, southern Vietnam, 2011. Emerg Infect Dis. 2012;18:2002–5. https://doi.org/10.3201/eid1812.120929

19. Thanh TT, Anh NT, Tham NT, Van HM, Sabanathan S, Qui PT, et al. Validation and utilization of an internally controlled multiplex real-time RT-PCR assay for simultaneous detection of enteroviruses and enterovirus A71 associated with hand foot and mouth disease. Virol J. 2015;12:85. https://doi.org/10.1186/s12985-015-0316-2

20. Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol. 2006;44:2698–704. https://doi.org/10.1128/JCM.00542-06

21. Tan V, Tuyen NT, Thanh TT, Ngan TT, Van HM, Sabanathan S, et al. A generic assay for whole-genome amplification and deep sequencing of enterovirus A71. J Virol Methods. 2015;215-216:30–6. https://doi.org/10.1016/j.jviromet.2015.02.011

22. Kroneman A, Vennema H, Deforce K, van der Avoort H, Peinaranda S, Oberste MS, et al. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol. 2011;51:121–5. https://doi.org/10.1016/j.jcv.2011.10.006

23. Tran CB, Nguyen HT, Phan HT, Tran NV, Wills B, Farrar J, et al. The seroprevalence and seroconcordance of enterovirus 71 infection in infants and children in Ho Chi Minh City, Viet Nam. PLoS One. 2011;6:e21116. https://doi.org/10.1371/journal.pone.0021116

24. Takahashi S, Metcalf CJE, Arima Y, Fujimoto T, Shimizu H, Rogier van Doorn H, et al. Epidemic dynamics, interactions and predictability of enteroviruses associated with hand, foot and mouth disease in Japan. J R Soc Interface. 2018;15:20180507. https://doi.org/10.1098/rsif.2018.0507

25. Ponn-Salort M, Grassy NC. Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science. 2018;361:800–3. https://doi.org/10.1126/science.aat6777

26. Huang SW, Tai CH, Fennville JM, Lin CH, Wang SM, Liu CC, et al. Mapping enterovirus A71 antigenic determinants from viral evolution. J Virol. 2015;89:11500–6. https://doi.org/10.1128/JVI.02035-15

27. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, Lin KH, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: implications for vaccination. PLoS Med. 2016;13:e1001958. https://doi.org/10.1371/journal.pmed.1001958

28. Liu L, Mo Z, Liang Z, Zhang Y, Li R, Ong KC, et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 2015;13:226. https://doi.org/10.1186/s12916-015-0448-7

29. Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016;13:e1001958. https://doi.org/10.1371/journal.pmed.1001958
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease

Appendix

Microneutralization Procedure

1. For each tested serum, first dilute the serum 4× in maintained medium (MM), then inactivate the diluted serum sample at 56°C for 30 minutes.

2. Add 125 μL MM to all wells of a 96-well U-bottom plate. Additionally, as negative controls, add 125 μL of MM to wells H1–H12.

3. Add 125 μL of the 4× diluted serum prepared above to wells A1–A4. The serum sample is now diluted 8× (1:8) in quadruplicate.

4. Next, transfer 125 μL of the 1:8 diluted serum from wells A1–A4 to wells B1–B2. The serum sample is now diluted 16× (1:16) in quadruplicate.

5. Continue this 2× dilution (step 4) until wells G1–G4 (1:512); that is, transfer 125 μL of the 1:16 diluted serum to wells C1–C4, and so on. Then, pipet out 125 μL of the diluted serum in wells G1–G4.

6. Add 125 μL of the working dilution (100 TCID₅₀) of the virus stock to all wells of the 96-well U-bottom plate containing prepared diluted serum samples, except wells H1–H12, which serve as negative controls.

7. For back-titration, prepare 10-fold dilution series (10⁻¹ to 10⁻⁴) of the working dilution of the virus stock.

8. Incubate the plate containing diluted serum samples and virus prepared in step 6 and 10-fold dilution series of the working dilution of the virus stock (step 7) at 37°C for 1 hr.
9. Retrieve the 96-well U-bottom plates pre-coated with rhabdomyosarcoma (RD) cells at \( \geq 90\% \) of confluence (prepared a day in advance) from the incubator, and discard the growth medium.

10. Wash the cells 2 times with PBS (150 \( \mu \)L/well each time).

11. Transfer 50 \( \mu \)L of the serum–virus mixture and negative controls prepared in step 6, and 50 \( \mu \)L each virus dilutions prepared for back-titration to the corresponding wells of 96-well U-bottom plates containing the RD cells (step 10).

12. Incubate the plates at 37°C for 1 hr.

13. Refeed all wells with 130 \( \mu \)L of MM.

14. Incubate plates at 37°C and 5% CO\(_2\) for 5 days.

15. Observe the cells daily for cytopathic effects and record the results.

### Appendix Table 1. Assessment of cross-neutralizing effects among CVA6, CVA10, CVA16, and EV-A71.

| Virus                        | Sero-status against CV-A6 | Sero-status against CV-A10 | Sero-status against EV-A71 |
|------------------------------|---------------------------|----------------------------|---------------------------|
| CV-A16 positive serum samples, N = 50 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 24 (48)                  | 26 (52)                  | 24 (48)                  | 26 (52)                  | 20 (40)          | 30 (60)          |
|                              | 1.31 (0.63–2.71)         | 0.32                      | 0.63                      |
| CV-A16 negative serum samples, N = 70 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 29 (41)                  | 41 (59)                  | 29 (41)                  | 41 (59)                  | 25 (36)          | 45 (64)          |
|                              | 0.48                      | 0.32                      | 0.63                      |
| EV-A71 positive serum samples, N = 45 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 19 (42)                  | 26 (58)                  | 25 (56)                  | 20 (44)                  | 20 (44)          | 25 (56)          |
|                              | 0.74 (0.42–1.86)         | 0.71                      | 0.63                      |
| EV-A71 negative serum samples, N = 75 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 34 (45)                  | 41 (55)                  | 39 (52)                  | 36 (48)                  | 30 (40)          | 45 (60)          |
|                              | 0.88 (0.42–1.86)         | 1.15 (0.55–2.42)         | 1.20 (0.57–2.54)         |
| CV-A10 positive serum samples, N = 64 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 27 (42)                  | 37 (48)                  | 24 (38)                  | 40 (62)                  | 25 (39)          | 39 (61)          |
|                              | 0.64 (0.41–1.73)         | 0.32                      | 0.71                      |
| CV-A10 negative serum samples, N = 56 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 26 (46)                  | 30 (54)                  | 26 (41)                  | 30 (59)                  | 20 (36)          | 36 (64)          |
|                              | 0.84 (0.41–1.73)         | 0.69 (0.33–1.44)         | 1.15 (0.55–2.42)         |
| CV-A6 positive serum samples, N = 53 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 27 (51)                  | 26 (49)                  | 24 (45)                  | 29 (55)                  | 19 (36)          | 34 (64)          |
|                              | 0.84 (0.409–1.734)       | 1.31 (0.628–2.71)        | 0.88 (0.42–1.86)         |
| CV-A6 negative serum samples, N = 57 | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) | positive, n (%) | negative, n (%) |
|                              | 37 (55)                  | 30 (45)                  | 26 (39)                  | 41 (61)                  | 26 (39)          | 41 (61)          |
|                              | 0.64 (0.41–1.73)         | 0.48                      | 0.74                      |
Appendix Figure 1. Graphs illustrating the kinetics of neutralizing antibody titers (in binary logarithm) against (A) CVA6 (p = 0.063), (B) CVA10 (p<0.01), (C) CVA16 (p = 0.098), and (D) EV-A71 (p = 0.50) in plasma samples collected at enrollment and follow-up from patients infected with CVA10.
Appendix Figure 2. Graphs illustrating the kinetics of neutralizing antibody titers (in binary logarithm) against (A) CVA6 (p = 0.202), (B) CVA10 (p = 1.0), (C) CVA16 (p<0.001), and (D) EV-A71 (p = 0.098) in plasma samples collected at enrollment and follow-up from patients infected with CVA16.
Appendix Figure 3. The association between antibody response (seropositive) and illness days at enrollment for individual groups of patients infected with (A) CVA6 \((p = 0.028)\), (B) CVA10 \((0.894)\), (C) CVA16 \((p = 0.125)\), and (D) EV-A71 \((p = 0.001)\).